RecruitingEarly Phase 1NCT06462508

Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study


Sponsor

Anhui Provincial Hospital

Enrollment

30 participants

Start Date

Apr 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[68Ga\]Ga-PSMA-11.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

Similar to the related study above, this trial compares [18F]F-PSMA-N5 with a different standard tracer, [68Ga]Ga-PSMA-11, for detecting and staging prostate cancer using PET/CT scans. **You may be eligible if...** - You are between 18 and 90 years old - You have confirmed or suspected prostate cancer, including recurrence after treatment - Complete MRI and clinical information (PSA, Gleason grade) is available - You agree to have both PET/CT scans within two weeks - You are willing to have a biopsy or have already had pathological confirmation **You may NOT be eligible if...** - You are unable to cooperate with scanning procedures - You have another active cancer - You have a known alcohol allergy - You have liver or kidney dysfunction Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]F-PSMA-N5

Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.

DRUG[68Ga]Ga-PSMA-11

Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.


Locations(1)

The First Affiliated Hospital of China University of Science and Technology(Anhui Provincial Hospital)

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06462508


Related Trials